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Inﬂuenza A and B viruses are responsible for annual epidemics and
result in increased morbidity and mortality in the human population
worldwide (Simonsen et al., 1997 #2230){Thompson et al., 2003
#18434}. Vaccination is the principal intervention for preventing
inﬂuenza and reducing the public health impact of epidemics and
pandemics. Various types of inﬂuenza vaccines have been available and
used for more than 60 years (Francis et al. 1947). They are safe and
effective inpreventingbothmild and severeoutcomesof inﬂuenza (Fiore
et al., 2009 #21592){Nichol, 2008 #18436}. Seasonal inﬂuenza vaccines
contain two type A viruses (H1N1 and H3N2) and one type B virus to
elicit immunity to currently circulating inﬂuenza viruses. Two major
types of inﬂuenza vaccines are licensed for human use – inactivated
inﬂuenza vaccine (IIV) and live attenuated inﬂuenza vaccine (LAIV). IIV
is administered parenterally and induces humoral IgG antibodies to
the hemagglutinin (HA). High serum antibody titers are correlated withhost protection against infection with antigenically similar viruses but
are less effective against antigenic variants of the virus.
In contrast to inactivated vaccines, LAIV administered intranasally
(i.n.) mimics natural infection and is capable of inducing a much
broader immune response. Besides eliciting humoral antibodies, LAIV
induces mucosal immunity that prevents virus infection at the portal
of entry and subsequent replication and spread in the respiratory
tract. In addition, LAIV can generate speciﬁc cytotoxic CD8+ T
lymphocytes that may confer heterosubtypic immunity, thus offering
a unique advantage over inactivated vaccines (Belshe et al., 2000a;
Belshe et al., 2000b; Cox et al., 2004; Kreijtz et al., 2009; Lu et al., 2006;
Nichol and Treanor, 2006; Powell et al., 2007; Rudenko et al., 1996;
Seo et al., 2007; Tamura et al., 2005).
Development of LAIV became possible with the generation of cold-
adapted viruses such as A/Ann Arbor/6/60 and A/Leningrad/134/17/
57 (Alexandrova and Smorodintsev, 1965; Maassab, 1967; Maassab et
al., 1969; Smorodintseff et al., 1937). These viruses met two critical
requirements for development of LAIV and their licensure for human
use (Glezen, 2004). First, the attenuating mutations present in the
attenuated master donor virus (MDV) must be within one or more of
the six RNA segments that do not encode the HA and NA glycoproteins
(Belshe et al., 1992; Jin et al., 2003; Snyder et al., 1988). Second, the
transfer of the six RNA segments encoding the internal viral proteins
(i.e., those that do not encode for HA or NA) from the attenuated MDV
to the new epidemic virus must retain the attenuating capacity,
Fig. 1. Infectious viral titers and plaque morphology of parental and RG-derived viruses
at permissive and restrictive temperatures. (A) Virus stocks propagated in MDCK cells
at the permissive temperature (33 °C) were titrated by plaque assay at the permissive
or restrictive temperatures (37 and 38 °C). The bars represent virus titers at indicated
temperature and the error lines represent standard deviation. (B) Plaque morphology
in MDCK cell monolayers incubated at the indicated temperatures, ﬁxed at 72 h after
infection and stained with crystal violet.
Table 1
Amino acid differences between caLen17 and Len134 virus sequences.
Protein Position wt A/Leningrad/134/57a ca A/Leningrad/134/17/57b
Amino acid Codon Amino acid Codon
PB2 478 Val GTA Leu TTA
PB1 265 Lys AAG Asn AAT
591 Val GTT Ile ATT
PA 28 Leu CTG Pro CCG
341 Val GTA Leu TTA
HA1c 181 Asn AAT Thr ACT
197 Val GTT Ile ATT
225 Met ATG Ile ATA
314d Thr ACA Ala GCA
HA2c 18 Ile ATTe Val GTT
NP 492d Asn AAT Ser AGT
NA 366 Ile ATC Thr ACC
M1 15 Ile ATC Val GTC
144 Phe TTT Leu TTG
NS2 100 Met ATG Ile ATA
a Wild-type parental virus from CDC repository.
b MDV derived from adaptation of egg-grown caLen17 to MDCK cells.
c Numbering from the N-terminal position of the H2 HA after cleavage by signalase.
d Mutations introduced during adaptation of egg-grown caLen17 to MDCK cells.
e Amino acid change speciﬁc for the wt strain used in this study and not reported before.
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wild-type inﬂuenza virus (Belshe et al., 1992; Murphy and Coelingh,
2002). Finally, the attenuated phenotype of the vaccine viruses must
be stable, virulent revertant viruses should not appear in vaccinees.
The LAIV currently licensed in the Russian Federation consists of
reassortant viruses with the HA and NA gene segments from currently
circulating wild-type (wt) viruses recommended by theWHO and the
six internal protein-encoding gene segments from the cold-adapted
MDVs A/Leningrad/134/17/57 (H2N2) (caLen17) or B/USSR/60/69
(B60) (Aleksandrova, 1977; Aleksandrova et al., 1971; Wareing et al.,
2001). The six genes encoding the internal proteins of theMDV impart
the cold-adapted (ca), temperature-sensitive (ts) and attenuation
(att) phenotypes to the vaccine viruses by preventing replication in
the lower respiratory tract of vaccinees (Aleksandrova et al., 1971;
Maassab et al., 1982; Wareing et al., 2001). The MDV caLen17 was
derived from wild-type A/Leningrad/134/57 (H2N2) (Len134) virus
after 17 sequential passages in embryonated chicken eggs at 25 °C and
was ﬁrst used in the 1960s as a LAIV for immunization of children
(Alexandrova and Smorodintsev, 1965).
Genome sequence comparison between parent Len134 and its
cold-adapted derivative revealed that a number of non-synonymous
mutations in internal protein-encoding genes occurred during low
temperature propagation in eggs (Klimov et al., 1992a). Some of these
mutations imparted ts, ca and att phenotypes of the MDV (Klimov
et al., 1992a). The ts phenotype is considered to be the most
signiﬁcant contributor to attenuation of virulence for humans since
it restricts viral replication to the upper respiratory tract. Mapping the
genetic loci responsible for the ts phenotype relied on single-gene
reassortants (SGR) derived by replacing each parental Len134 gene
with the corresponding gene from a ca donor virus using classical
reassortment techniques (Kilbourne, 1969). These studies revealed
that the PB2 and PB1 genes imparted the ts phenotype (Klimov et al.,
2001). Analysis of single and multiple gene reassortants between
caLen17 and heterologous subtype H1N1 and H3N2 viruses conﬁrmed
the critical role of PB2 in conferring ts phenotype and the signiﬁcant
contribution of PB1 and PA, by so-called “gene constellation” effects
(Kiseleva et al., 2003). However, the ts phenotype of caLen17 was not
mapped to speciﬁc amino acids within the polymerase proteins where
more than one mutation was present. In this study, we developed an
eight plasmid-based reverse genetics system for the MDV caLen17
and used it to identify the role of each amino acid substitution in the ts
phenotype (Hoffmann et al., 2000a). We found that mutations within
PB2 and PB1 play a crucial role in the ts phenotype with possibly a
minor additional role for NS2 and conversely, restoration of mutations
in these genes was required to fully revert a ts 6:2 genotype vaccine
virus to that of wild-type virus.
Results
Generation of caLen17-rg virus from plasmid DNA
A set of eight ambisense plasmids carrying the genes from the
original MDV caLen17 was constructed by inserting full-length viral
cDNAs between the Pol I and Pol II promoters (Hoffmann et al.,
2000b). Infectious virus was recovered from the transfected cells and
termed caLen17-rg. Full genome sequencing of the rescued virus
conﬁrmed complete identity with MDV caLen17 in all viral genes.
Analysis of virus replication in MDCK cells at restrictive temperatures
showed that the caLen17-rg virus derived by reverse genetics (RG)
exhibited a ts phenotype like its parental caLen17 virus; both viruses
replicated efﬁciently at 33 °C but their replication at 38 °C, and even at
37 °C was severely impaired (Fig. 1A). In addition, these viruses
formed distinct plaques in MDCK cells at 33 °C while either few or no
plaques were observed at 38 °C (Fig. 1B). These data indicate that the
established reverse genetics system for MDV caLen17 allows recovery
of phenotypically indistinguishable viruses entirely from plasmidDNA and provides the means to manipulate the viral genome using
standard molecular genetics techniques.
Generation of Len134-rg virus
To generate a reverse genetics system for the wild-type (wt)
parent of the MDV caLen17, we modiﬁed the plasmid set used to
derive caLen17-rg by site-directed mutagenesis to obtain the
sequences of the ancestral wt Len134 genes. Alignment of the two
genomes revealed 15 non-synonymous nucleotide changes distribut-
ed throughout the genome (Table 1). Mutation in codon 492 of the NP
gene and codon 314 of the HA1 gene were noted in the MDCK-grown
MDV caLen17 but were absent in the original egg-grown caLen17
stock. However, the latter could not affect the ts phenotype of
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synonymous changes were changed in the caLen17-rg plasmid set to
obtain parental wt Len134 genes (Table 1). A virus designated
Len134-rg was rescued at 37 °C with a genomic sequence identical to
that of the transfected plasmid DNAs. Comparative analyses of
Len134-rg and wt Len134 virus replication in MDCK cells revealed
that they both had similar titers in plaque assays at 33, 37 and 38 °C
(Fig. 1A); i.e., statistically, their titers were not signiﬁcantly different.
The two viruses also yielded morphologically identical plaques at all
tested temperatures (Fig. 1B). The newly established reverse genetics
systems for caLen17 (caLen17-rg) and the parental wt virus Len134
(Len134-rg) are suitable for evaluating the genetic basis of the ts
phenotype.
Identiﬁcation of the viral genes that determine the ts phenotype
Early genetic analyses suggested the possible involvement of ﬁve
viral genes in the ts phenotype of caLen17: PB2, PB1, PA, M1/M2 and
NS1/NS2 proteins (Ghendon et al., 1981). However, subsequent
molecular studies revealed that the PA, M and NS proteins did not
contribute to this trait (Klimov et al., 2001). As a ﬁrst step towards
dissecting the genetic basis of the ts phenotype of caLen17, we used a
genetic approach to study the contribution of each of the six internal
gene segments (PB2, PB1, PA, NP, M, NS). To this end, we created
single-gene reassortants (SGRs) carrying one gene from caLen17-rg
and the rest of the genome from Len134-rg.
Comparable infectious titers were obtained for the PA, NP or M SGR
viruses at permissive and restrictive temperatures; titer reduction
values at 38 °C did not exceed 0.7 log10 and the difference with Len134-
rg virus was not statistically signiﬁcant (Fig. 2A; P values of 0.147, 0.096
and 0.38, respectively). In contrast, the introduction of ca PB2 or PB1
segments resulted in viruses that were ts at 38 °C (~450–1300 fold
reduction of infectious titer; P=0.0002 and 0.0001, respectively, when
compared to Len134-rg). Nevertheless, these SGR viruses showed
relatively minor titer reductions at 37 °C; their subtle replication
impairment was reﬂected in plaque morphology alterations (compare
Len134-rg with PB2-SGR and PB1-SGR in Fig. 2B). Noteworthy, the SGRFig. 2. Replication of parental (Len134-rg and caLen17-rg) and reassortant (6:2 and SGRs
propagated in MDCK cells at the permissive temperature (33 °C) were titrated by plaque ass
fold reduction of virus titers (log10) at 37 and 38 °C relative to 33 °C and the error lines repre
Len134-rg and indicated virus. (B) Plaque morphology in MDCK cell monolayers, as describwith the ca NS gene had 10-fold lower infectivity at the restrictive
temperature of 38 °C. This mutant virus was signiﬁcantly more
temperature sensitive than Len134-rg (Fig. 2A; P = 0.023), but also
signiﬁcantly (P = 0.005) less temperature sensitive than PB2-SGR and
PB1-SGR, suggesting that the M100I amino acid substitution in the NS2
protein may play a minor role in the caLen17 ts phenotype.
To ascertain the maintenance of the ts phenotype in viruses with
wild-type HA and NA, i.e., with the genotype of vaccine reassortants, a
prototype virus which carries six genes encoding the internal proteins
from cold-adapted caLen17 and HA and NA fromwt Len134 virus (so-
called 6:2 reassortant genotype) was analyzed. The 6:2 RG virus
showed a 20,000-fold reduced titer at 38 °C compared to Len134-rg,
and was indistinguishable from the caLen17-rg, conﬁrming that the
wt HA and NA genes do not interfere with expression of the ts
phenotype of caLen17 (Fig. 2A, vaccine 6:2 reassortant compared to
Len134-rg and caLen17-rg viruses).Identiﬁcation of speciﬁc amino acid substitutions responsible for the
viral ts phenotype
To determine the speciﬁc residues responsible for expression of the
ts phenotype by the caLen17 virus, we generated RG viruses including
one or more amino acid substitutions from the caLen17 virus into a wt
Len134 background. Three mutations in PB2 and PB1 genes were of
particular interest since their SGRs showed the most signiﬁcant
alteration of virus replication at restrictive temperatures. The separate
introduction of the PB1265N or PB1591I amino acid substitutions into wt
Len134 virus decreased virus titers at 38 °C by 1.8 and 0.7 log10,
respectively (P=0.0001 for PB1265N and P=0.028 for PB1591I mutants
compared to Len134-rg), but had no effect on virus replication at 37 °C
(Fig. 3A). Interestingly, the K265N substitution alone signiﬁcantly
impaired plaque formation at 38 °C, decreasing plaque size, whereas
the V591I change in PB1 only slightly affected plaque morphology at
the restrictive temperature (Fig. 3B, mutants PB1265N and PB1591I
compared to Len134-rg). Nevertheless, these two substitutions
combined, resulted in a signiﬁcant replicative impairment at the) viruses in MDCK cells at permissive and restrictive temperatures. (A) Virus stocks
ay at the permissive or restrictive temperatures (37 and 38 °C). The bars represent the
sent standard deviation. * denotes statistically signiﬁcant difference (P b 0.05) between
ed in Fig. 1.
Fig. 3. Replication of wt and mutant viruses at permissive and restrictive temperatures.
RG viruses possessing one or more mutations from MDV caLen17 in Len134-rg
background compared to 6:2 genotype vaccine prototype virus. (A) Virus stocks
propagated in MDCK cells at the permissive temperature (33 °C) were titrated by
plaque assay at the permissive or restrictive temperatures (37 and 38 °C). The bars
represent the fold reduction of virus titers (log10) at 37 and 38 °C relative to 33 °C and
the error lines represent standard deviation. * denotes statistically signiﬁcant difference
(P b 0.05) between Len134-rg and indicated virus. (B) Plaque morphology at indicated
temperatures as in Fig. 1.
300 I. Isakova-Sivak et al. / Virology 412 (2011) 297–305restrictive temperature 38 °C (P = 0.018 if PB1265N mutant in Fig. 3A
(1.7 log10 decrease) is compared with PB1-SGR (3.1 log10) in Fig. 2A).
Surprisingly a RG virus combining the single PB2 substitution and
K265N change in PB1 failed to yield a genetically stable population of
PB2478L/PB1265N virus; full-genome sequence analysis of viruses
rescued from several independent transfections revealed multiple
heterogeneous sequence variants (with N30% mixed sequence popula-
tions)within the polymerase genes. In contrast, the PB1591I substitution
was compatible with PB2478L, the dual-substitution virus was severely
impaired at the restrictive temperature of 38 °C (4.5 log10 titer
reduction) indicating that the V591I PB1 change enhanced the effect
caused by PB2478L (3 log10 titer reduction) (P = 0.017 if PB2-SGR in
Fig. 2A is compared with mutant PB2478L/PB1591I in Fig. 3A). Further-
more, the three mutations in PB2 and PB1 combined resulted in a virus
with replication characteristics virtually undistinguishable from those
of the 6:2 genotype vaccine virus prototype (P values of 0.88 and 0.25
when vaccine 6:2 reassortant is compared to PB2478L/PB1265N,591I
mutant at 37 and 38 °C, respectively; Fig. 3A). The triple-substitution
failed to form plaques at 38 °C and yielded extremely small plaques at
37 °C, whereas all mutants with only one or two substitutions (viruses
PB2-SGR, PB1-SGR, PB1265N, PB1591I and PB2478L/PB1591I) were able to
form readily visible plaques at 37 °C, and in some cases even at 38 °C
(Figs. 2B and 3B).Fig. 4. Replication of wt, 6:2 genotype vaccine prototype virus and mutants with one or
more reverted mutations from vaccine 6:2 reassortant. (A) Virus stocks propagated in
MDCK cells at the permissive temperature (33 °C) were titrated by plaque assay at the
permissive or restrictive temperatures (37 and 38 °C). The bars represent the fold
reduction of virus titers (log10) at 37 and 38 °C relative to 33 °C and the error lines
represent standard deviation. (B) Plaque morphology at indicated temperatures as in
Fig. 1.Identiﬁcation of mutations critical for maintenance of the ts phenotype
in a 6:2 reassortant
The safety of LAIV based on MDV caLen17 could be seriously
compromised by the emergence of revertant viruses which lost the
attenuation phenotype imparted by tsmutations. To determine which
mutations are critical for the expression of the ts phenotype, weanalyzed a panel of viruses with single or clustered substitutions that
revert the amino acid(s) to wild-type in a caLen17 background. In an
attempt to increase the relevance of the study for vaccine reassortant
viruses, these changes were introduced by RG into the genome of a
6:2 reassortant with wt HA and NA and the remaining genes from
caLen17. Replacement of the PB2 or the PB1 gene with the
corresponding wild-type gene segment changed the vaccine 6:2
virus ts phenotype at 37 °C; i.e., titers at 37 °C were similar to those at
the permissive temperature 33 °C. In contrast, these viruses remained
highly impaired at 38 °C, showing ~4 log10 reduction in replication at
this temperature (Fig. 4A, mutants PB2478V and PB1265K,591V) whereas
the PB2478V/PB1265K double mutant was essentially indistinguishable
from the Len134-rg strain in terms of infectious titers at the restrictive
temperature (Fig. 4A, P = 0.21). However, this mutant formed
pinpoint plaques at 38 °C, unlike thewild-type virus (comparemutant
PB2478V/PB1265K with Len134-rg in Fig. 4B). Interestingly, the
reversion of the third ts mutation PB1-591V changed plaque
formation at restrictive temperatures although plaque morphology
of the PB2478V/PB1265K,591V mutant still seemed to differ somewhat
from Len134-rg virus (Fig. 4B).
Since experiments with single-gene reassortants revealed that
amino acid substitution M100I in NS2 protein could affect plaque
morphology at high temperature, we reverted this mutation as well,
in addition to the three mutations in the PB2 and PB1 genes.
Noteworthy, the mutant PB2478V/PB1265K,591V/NS2100M showed clear
and distinct plaque formation at 38 °C comparable to Len134-rg
(Fig. 4B).
These data, therefore, show that mutations in the two polymerase
genes, PB2 and PB1, are themajor determinants of the ts phenotype. In
PB1, the mutation at position 591 seems to contribute to a lesser
extend as compared to themutation at position 265. These results also
suggest that there may be a minor additional role for the mutation in
NS2. We conclude that reversion of all these mutations is required for
complete restoration of a wt phenotype in a 6:2 reassortant vaccine
virus.
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divergent virus
To determine whether transferring the genetic signature of the
caLen17 ts phenotype into a divergent strain would impart this
phenotype, four ts mutations were introduced by RG into the wild-
type PR8 virus: PB2 (V591I), PB1 (K265N; V591I) and NS2 (M100I).
Altogether, eight mutant viruses were generated with amino acid
substitutions as shown in Fig. 5. The temperature-sensitive phenotype of
the RG viruses was examined by plaque assay in MDCK cells at various
temperatures. As expected, the introduction of caLen17 tsmutations into
a PR8 backbone had dramatic effect on plaque titers at restrictive
temperatures. Thus, the PB2478L mutation itself was enough to impair
the replication of PR8 virus at 38 °C; a 2.0 log10 plaque titer reduction
and signiﬁcantly smaller plaque size were observed, compared to those
at permissive temperature (Fig. 5A, B). In contrast, two other mutations
within the PB1 gene (variants PB1265N and PB1591I) failed to signiﬁcantly
reduce the virus titer at 38 °C. Nevertheless, these two mutations
combined (mutant PB1265N,591I), reduced virus titer at 38 °C by as much
as 1.25 log10 (Fig. 5A). Even though mutation PB1265N did not change
signiﬁcantly the virus titer at restrictive temperatures, when combined
with the ts mutation in the PB2 protein (mutant PB2478L/PB1265N) a
dramatic effect on virus titer at 37 and 38 °C was observed, with 1.8 and
4.2 log10 reductions, respectively. The other ts mutation PB1591I had a
somewhat lesser effect on virus titer at restrictive temperatures when
combined with PB2478L (variant PB2478L/PB1591I) and/or PB1265N
(mutant PB1265N,591I) ts mutations. In summary, these results show
that replication of a RG-derived mutant virus possessing these three ts
mutations (PB2478L/PB1265N,591I) was severely impaired at both 38 and
37 °C, like the original MDV caLen17 (Fig. 5A).
Additionally, each of the threemutations in different combinations
affected plaque formation at restrictive temperatures. The PB1265N
mutation inserted singly into PR8 virus imparted small size plaques at
38 and 37 °C (Fig. 5B), and a similar outcome was noted when this
mutation was introduced in combination with one or two other ts
mutations (Fig. 5B, mutants PB1265N,591I, PB2478L/PB1265N and PB2478L/Fig. 5. Infectious viral titers and plaque morphology of wtPR8 virus and PR8 mutants carry
propagated in eggs at the permissive temperature (35 °C) were titrated by plaque assay at th
titers at indicated temperature and the error lines represent standard deviation. (B) PlaquePB1265N,591I). As expected, the PB1591I mutation had the least impact
on plaque formation, which could be observed only in combination
with the PB2478L and/or PB1265N mutation. Interestingly, introducing
the M100I mutation into the NS2 protein of PR8 virus had no effect on
virus plaque formation at 38 °C (Fig. 5A, B; mutant NS2100I). In
summary, in agreement with the ﬁndings from MDV caLen17, ts
mutations in both PB2 and PB1 genes could impart a ts phenotype into
a divergent virus such as PR8, and conﬁrmed the dominant role of
PB2478L and PB1265N ts mutations.
Discussion
Live attenuated inﬂuenza vaccine (LAIV) based on ca viruses
derived from the wt A/Leningrad/134/57 (H2N2) (Len134) virus has
been used in Russia for decades and proven to be safe, immunogenic
and efﬁcacious in children, adults and elderly (Rudenko and
Alexandrova, 2001; Rudenko et al., 1996; Rudenko et al., 1993). Two
different viruses were used as master donors for type A LAIV until
2004: A/Leningrad/134/17/57 (caLen17) to produce vaccine for adults
(Alexandrova and Smorodintsev, 1965) and A/Leningrad/134/47/57
(caLen47) for children (Garmashova et al., 1984). MDV caLen17 was
derived from Len134 virus by 30 passages in eggs at 32 °C followed by
17 passages at 25 °C, resulting in multiple mutations (Table 1). The
caLen47 MDV was derived from caLen17 by 30 passages in eggs at 25
°C, resulting in four additional amino acid changes: PB2-S492R,
PB1-M317I, NP-L341I and M2-A86T (Klimov et al., 1992a).
Currently, the type A components of Russian LAIVs contain the six
gene segments encoding the internal proteins (PB2, PB1, PA, NP, M
and NS) of the cold-adapted master donor virus caLen17, which
confer temperature sensitivity (ts), cold adaptation (ca) and attenu-
ation (att) phenotypes, while the antigenic characteristics are
transferred with the HA and NA genes from a circulating wild-type
virus (6:2 vaccine genotype). Reduced replication at core body
temperature will restrict replication of LAIV viruses to the upper
respiratory tract of vaccinees and minimize disease symptoms
(Richman and Murphy, 1979). Ferrets inoculated with selecteding one or more caLen17-speciﬁc mutations at various temperatures. (A) Virus stocks
e permissive (33 °C) or restrictive temperatures (37 and 38 °C). The bars represent virus
morphology at indicated temperatures as in Fig. 1.
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revealed that the ca phenotype was not correlated with virulence in
this model (Klimov et al., 2001). In contrast, all viruses with ts
phenotype were attenuated for animals, i.e., no viral replication was
detected in lungs, whereas all reassortants with non-ts phenotype
could replicate efﬁciently in ferret lungs. Therefore, the ts phenotype
is directly linked to attenuation and identiﬁcation of the underlying
mutations is of considerable interest.
The early attempts to identify the genes of caLen17 that impart
the ts phenotype to reassortant vaccine viruses utilized classical
genetic reassortment between caLen17 and genetically divergent
epidemic viruses. The use of wild-type (wt) viruses which differed
from each other with respect to replication properties at varying
temperatures has led to diverse conclusions depending on the virus
chosen for reassortment (Kiseleva et al., 2003). Nevertheless,
elaborate studies of large numbers of reassortants between
caLen17 and diverse wt viruses, led to the conclusion that the PB2
protein was a major determinant of the ts phenotype, with the other
polymerase genes, PB1 and PA, as signiﬁcant contributors (Kiseleva
et al., 2003). More precise experiments with single-gene reassor-
tants (SGRs) between genetically related viruses, pointed towards a
leading role for PB2 and PB1 genes in conferring the ts phenotype
(Klimov et al., 2001). The genetic composition of reassortant viruses
in these studies was determined by RT-PCR followed by RFLP
(Klimov et al., 1992b), without full-genome sequencing. Selection
for desired genotypes often required multiple passages at restrictive
temperature, increasing the risk of unwanted mutations within any
gene segment, complicating the interpretation of results. In addition,
the origin of the HA and NA genes was often unknown. In one study a
ts mutation has been mapped to the HA gene (Medvedeva et al.,
1991), but this is considered irrelevant as vaccine viruses do not
contain HA of caLen17.
Here we report the use of reverse genetics system for MDV caLen17
to systematically map the mutations that determine the ts phenotype.
After constructing a RG system for caLen17, we engineered the original
wt parental Len134 virus from caLen17 by reverting 14 nucleotide
changes in the latter virus. The creation of two highly isogenic
recombinant viruses with a deﬁned number of amino acid differences
allowed us to map the virus ts phenotype to speciﬁc mutations,
avoiding any problems of gene constellation effects.
The ts viral phenotypes of mutant viruses were assessed at 37 and
38 °C, since the replication of caLen17 in MDCK cells is signiﬁcantly
impaired at these temperatures (as compared to 32 °C). In contrast,
wild-type Len134 virus replicates efﬁciently at 37 and 38 °C (Kiseleva
et al., 2004). However, incubation at 39 °C restricted Len134 virus
replication (Kiseleva et al., 2004). Interestingly, the cut-off tempera-
tures for A/Ann Arbor/6/60 (H2N2) (A/AA) MDV were 38 and 39 °C,
optimal for replication of wt strain and restrictive for caA/AA (Jin et al.,
2003; Jin et al., 2004). Furthermore, a study by Kiseleva et al. indicated
that the same viruses could have different temperature sensitivity
proﬁles in eggs or MDCK cells (Kiseleva et al., 2004).
We conﬁrmed that mutations in the PB2 and PB1 proteins were
critical contributors to the ts phenotype, as reported previously
(Klimov et al., 2001). Both PB2 and PB1 genes inserted individually
into the wt genetic background could impart the ts phenotype.
Furthermore, Len134 SGRswith the caLen17 PB2 or PB1 (PB2-SGR and
PB1-SGR) were completely attenuated for ferrets, emphasizing the
association between attenuation and the ts phenotype (Klimov et al.,
2001). We further showed that mutations within PA, NP and M genes
had no effect on the expression of the ts phenotype, which also
correlated well with an earlier study (Klimov et al., 2001).
Using a reverse genetics approach we identiﬁed the role of single
mutations within the PB1 gene. Mutation PB1265N had greater impact
on virus ts phenotype than PB1591I. Interestingly, a recent study of ts+
revertants from a related MDV A/Leningrad/134/47/57 (H2N2)
reached different conclusions (Tsfasman et al., 2007) possiblyresulting from the use of fowl plague virus as a reassortment partner
to analyze the ts mutations.
In concordance with previous studies, we found that introduction
of all three ts mutations into PB2 and PB1 genes of wt Len134 virus
was sufﬁcient to completely transfer the ts phenotype from MDV
caLen17 (Kiseleva et al., 2003). Unlike previous studies, we noticed
some effect of mutation M100I in the NS2 protein, which caused virus
titer reduction at 38 °C as much as 1.0 log10 PFU/ml, and reduced
plaque size at this temperature compared to 33 °C. Probably, this
discrepancy with previous studies could be explained by the criteria
chosen for ts phenotype assessment. Originally, the phenotype of
mutant viruses was assessed by comparing their titers in eggs at 33 °C
versus 40 °C (Klimov et al., 2001), and lately, in MDCK cells at 33 °C
versus 37 °C (Kiseleva et al., 2003). Here the effect of NS2 mutation
was observed in MDCK cells only at 38 °C whereas no signiﬁcant virus
titer decrease at 37 °C was noticed. Importantly, according to the
regulations of Russian Ministry of Health, in addition to 6:2
reassortants, vaccine reassortants for LAIV may also contain ﬁve
genes from MDV and three genes from a wild-type strain (i.e., 5:3
genotype) (Anonymous, 2004). The identiﬁcation of a mutation in NS
with a role (albeit a minor one) in imparting the ts phenotype
indicates that LAIV should not include this gene segment from wt
virus.
The stability of this vaccine virus ts phenotype has been
demonstrated in numerous studies including in vitro experiments
(Kiseleva and Klimov, 2002), animal models (Marsh et al., 2003) and
clinical trials (Klimov et al., 2001; Klimov et al., 1995). In our study we
attempted to understand the genetic basis of this stability, or in other
words, the elimination of which ts mutations within a vaccine strain
would be sufﬁcient to revert the virus to a wt phenotype. Our results
show that the removal of the two main ts mutations (PB2478L and
PB1265N) in a 6:2 genotype vaccine virus had critical inﬂuence on the
virus ts phenotype. Nevertheless, the exclusion of two additional
mutations (PB1591I and NS2100I) was required to completely revert
the virus phenotype to that of wt strain. These data support the idea
that a combination of mutations was selected during the cold
adaptation process, This co-evolution of changes may explain the
demonstrated genetic stability of vaccine strains after replication in
susceptible hosts.
To determine whether the ts mutations of MDV caLen17 can
impart the ts phenotype to a divergent virus, we created A/PR/8/34
(H1N1) viruses by RG with different combinations of ts mutations
from MDV caLen17. The fact that introducing certain amino acid
changes within polymerase genes of the PR8 strain led to loss of the
wt phenotype, reinforce the evidence that those changes act together
in an interdependent fashion. Unlike polymerase genes, the ts
mutation in the NS gene of caLen17 had no effect on the ts phenotype
of PR8 virus, suggesting that this mutationmay only play an accessory
role. It would be of great interest to ﬁnd out whether the caLen17-
speciﬁc mutations in PR8 background are preserved during multiple
passages in host cells.
Analogous studies have been done for A/Ann Arbor/6/60, the
master donor virus for the LAIV (FluMist) licensed in the US for use
in healthy individuals aged 2–49 years. The ts phenotype of this
strain was mapped to ﬁve ts loci distributed in three proteins: PB1
(E391, G581, T661), PB2 (S265) and NP (G34) (Jin et al., 2003; Jin et
al., 2004). The fact that both cold-adapted strains have the strongest
ts determinants in the polymerase proteins suggests a critical role of
those mutations in alteration of viral polymerase activity at
restrictive temperatures. Experiments with an inﬂuenza minige-
nome assay indeed demonstrated reduced polymerase activity of A/
AA MDV at 39 °C (Jin et al., 2004), but more comprehensive analysis
of molecular mechanisms of A/AA temperature sensitivity did not
reveal signiﬁcant effect of impaired polymerase function on viral
mRNA transcription and protein synthesis at restrictive temperature
(Chan et al., 2008). More probably, the interaction of polymerase
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mutant viruses to grow efﬁciently at high temperature. As was
demonstrated for caA/AA strain, ts mutations located in the PB1
protein could signiﬁcantly affect nuclear-cytoplasmic export of vRNP
and reduce M1 protein incorporation into virions at restrictive
temperature, which requires interaction with host cell proteins, such
as Hsp70 (Chan et al., 2008). The precise molecular mechanisms
underlying the ts phenotype of MDV caLen17 are not known and
worthy of further research.
Materials and methods
Cells, viruses and plasmids
Madin–Darby canine kidney (MDCK) and 293T human embryonic
kidney (HEK293T) cells were obtained from American Type Culture
Collection (ATCC) and were maintained in DMEM (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum. Cold-
adapted A/Leningrad/134/17/57 (H2N2) MDV (caLen17) was
obtained from Nobilon Schering-Plough (the Netherlands). This
virus was derived from an original egg-isolated caLen17 stock
(Aleksandrova et al., 1965) and propagated in MDCK cells at
permissive temperature (32–34 °C) followed by plaque puriﬁcation.
A working stock of caLen17 virus was prepared in MDCK cells by
infection at an MOI of 0.0001 at permissive temperature. Wild-type
A/Leningrad/134/57 (H2N2) (Len134) virus was from the CDC
repository. This virus was ampliﬁed in MDCK cells at 37 °C to prepare
a working stock.
A set of eight dual-promoter plasmids carrying all gene segments
of A/PR/8/34 (H1N1) (PR8) was used in this study to generate mutant
viruses with ts signatures fromMDV caLen17 (Hoffmann et al., 2000a;
Subbarao et al., 2003). Site-directedmutagenesis of PR8-PB2, PR8-PB1
and PR8-NS plasmids was performed using QuikChange XL Multi site-
directed mutagenesis kit (Stratagene, La Jolla, CA) to introduce
caLen17-speciﬁc mutations into the PR8 background.
Cloning of all genes from MDV caLen17 into dual-promoter plasmids
Viral RNA of caLen17was extracted using a QIAampViral RNAMini
Kit (Qiagen, Valencia, CA). Viral cDNA segments representing the
complete genome of caLen17 virus were ampliﬁed by RT-PCR with a
set of universal segment-speciﬁc primers (Hoffmann et al., 2001)
using One-Step RT-PCR Kit (Qiagen, Valencia, CA). The ampliﬁed DNA
segments subsequently were cloned into a dual-promoter plasmid for
inﬂuenza A reverse genetics (Fodor et al., 1999; Hoffmann et al., 2001;
Subbarao et al., 2003). The sequence of all the inserts was veriﬁed and
site-directed mutagenesis performed to render them identical to the
original virus. Site-directed mutagenesis was performed when
needed using the QuikChange XL site-directed mutagenesis kit
(Stratagene, La Jolla, CA) according to the manufacturer's protocol.
Derivation of inﬂuenza viruses by reverse genetics
DNA from a set of eight plasmids was transfected into co-cultured
HEK293T/MDCK cells using TransIT LT-1 transfection reagent (Mirus,
Madison,WI) according to themanufacturer's protocol. Four days after
transfection, culture supernatants and cell lysates were collected and
the recovered viruses were ampliﬁed twice in MDCK cells infected at
an MOI of 0.0001 in the presence of 1 μg/ml TPCK-treated trypsin
(Sigma-Aldrich, St. Louis, MO). Culture supernatants were harvested
when ~95% of the cells showedmorphologic changes, clariﬁed by low-
speed centrifugation, and stored at −80 °C until use. Viruses were
propagated at the permissive temperature (33 °C) after transfections
(HEK293T) or infections (MDCK). Reassortant H2N2 viruses were
generated in compliance with the Institutional Biosafety Committee
and NIH Guidelines for Research Involving Recombinant DNAMolecules. Wild-type H2N2 viruses were handled in biosafety level 3
containment facilities (CDC/NIH, 2007).
To generate mutant viruses with the A/PR/8/34 (PR8) genomic
backbone, 293T cells were transfected with eight plasmid DNAs
carrying wild-type or mutated genes from PR8. Three to four days
later, transfected cells were resuspended in the culture media with a
scraper and inoculated into eggs. Allantoic ﬂuid was harvested 48
h after inoculation and the presence of virus was revealed by
agglutination of turkey red blood cells (WHO, 2002). Working stocks
of reverse genetics-derived viruses were ampliﬁed in eggs and stored
at −80 °C. The complete genomes of all viruses derived by reverse
genetics were sequenced and any stocks containing spontaneous
mutations (including quasispecies) in any of the eight viral genes
were discarded and re-derived with a conﬁrmed correct sequence.
Virus replication studies
To determine virus replication at different temperatures, the
infectious viral titers were measured by plaque assay in MDCK cells.
To this end, six-well plates were seededwith 1 × 106 cells per well the
day before virus inoculation. Cell monolayers were rinsed twice with
PBS prior to inoculation with 200 μl of 10-fold dilutions of virus in
DMEM (Invitrogen, Carlsbad, CA) supplemented with TPCK-treated
trypsin (1 μg/ml). After adsorption at 33 °C for 1 h, the virus inocula
were removed, cells rinsed with PBS and immediately overlayed
with 3ml of 0.8% agarose mixture (prepared bymixing equal volumes
of 1.6% agarose (Lonza, Rockland, ME) and 2× MEM (Invitrogen,
Carlsbad, CA) supplemented with TPCK trypsin at ﬁnal concentration
of 1 μg/ml) per well. Plates were incubated at 33, 37 or 38 °C. After 3
days of incubation, the agarose overlay was carefully removed
and the cell monolayers were stained with Crystal-Violet (0.05%
solution in formalin) to visualize and enumerate plaques. Virus
endpoint dilution titers were expressed as log10 PFU/ml. The
lower limit of detection was 0.7 log10, and therefore, temperature-
sensitive viruses which did not form plaques at 10-3 dilution were
assigned a hypothetical maximum titer of 3.7 log10, in order to allow
calculation of reduction in virus titer. For statistical analysis, titration
of each virus at different temperatures was performed at least three
times.
Phenotypic and genetic analyses
The ts phenotype of the parent and RG viruses was assessed by
evaluating viral replication in MDCK cells at permissive (33 °C) and
restrictive temperatures (37 and 38 °C). Viruses that displayed 100-fold
or greater reduction in viral titers at the restrictive temperatures
compared with that observed at the permissive temperature were
considered ts.
Genetic analysis of all viruses was performed by nucleotide
sequencing using a BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems) and a 3130xl Genetic Analyzer (Applied
Biosystems) according to the instructions of the manufacturer.
Sequences were analyzed using BioEdit software.
Statistical analyses
Data were analyzed with the Statistica software (version 6.0; Statsoft
Inc.). Statistical signiﬁcance between log10 reduction values in viral titers
of different viruses was determined by Student's t-test. P values of b0.05
were considered signiﬁcant.
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